{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T02:34:45Z","timestamp":1781231685804,"version":"3.54.1"},"reference-count":60,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CMAR"],"DOI":"10.2147\/cmar.s287904","type":"journal-article","created":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T10:10:11Z","timestamp":1655115011000},"page":"1945-1960","source":"Crossref","is-referenced-by-count":12,"title":["Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy"],"prefix":"10.2147","volume":"Volume 14","author":[{"given":"Elisa","family":"Tassinari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Mollica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Nuvola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7892-9619","authenticated-orcid":true,"given":"Andrea","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Rosellini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6476-6871","authenticated-orcid":true,"given":"Francesco","family":"Massari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,6]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.pathol.2020.09.004","volume":"53","author":"Takahara","year":"2021","journal-title":"Pathology"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.eururo.2017.07.036","volume":"73","author":"Roupr\u00eat","year":"2018","journal-title":"Eur Urol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1001\/jama.2020.17598","volume":"324","author":"Lenis","year":"2020","journal-title":"JAMA"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","volume":"23","author":"Von der Maase","year":"2005","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"4454","DOI":"10.1200\/JCO.2008.20.5534","volume":"27","author":"Bellmunt","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1002\/cncr.10782","volume":"95","author":"Vaughn","year":"2002","journal-title":"Cancer"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1200\/JCO.1997.15.5.1853","volume":"15","author":"McCaffrey","year":"1997","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/sj.bjc.6604113","volume":"98","author":"Han","year":"2008","journal-title":"Br J Cancer"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1093\/annonc\/mdq398","volume":"22","author":"Albers","year":"2011","journal-title":"Ann Oncol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.3390\/cancers12061449","volume":"12","author":"Mollica","year":"2020","journal-title":"Cancers"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1200\/JCO.2011.34.8433","volume":"29","author":"Galsky","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1200\/JCO.2011.37.3571","volume":"30","author":"De Santis","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat Genet"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1007\/s40265-017-0748-7","volume":"77","author":"Farina","year":"2017","journal-title":"Drugs"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1200\/JCO.19.01213","volume":"38","author":"Vuky","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"738","DOI":"10.3390\/cancers12030738","volume":"12","author":"Vaddepally","year":"2020","journal-title":"Cancers"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1158\/2326-6066.CIR-15-0064","volume":"3","author":"Emens","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","volume":"395","author":"Galsky","year":"2020","journal-title":"Lancet"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","volume":"22","author":"Powles","year":"2021","journal-title":"Lancet Oncol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1016\/S1470-2045(20)30541-6","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol"},{"key":"ref25","unstructured":"Christopher JDW. First-line pembrolizumab with or without lenvatinib in patients with advanced urothelial carcinoma (LEAP-011): a Phase 3, randomized, double-blind study. Abstract from the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, Thursday Feb 17 \u2013 Saturday Feb 19; 2022."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1200\/JCO.2022.40.6_suppl.487","volume":"40","author":"Powles","year":"2022","journal-title":"J Clin Oncol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s00262-006-0266-z","volume":"56","author":"Nakanishi","year":"2007","journal-title":"Cancer Immunol Immunother"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3390\/cancers13010131","volume":"13","author":"Lopez-Beltran","year":"2021","journal-title":"Cancers"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.eururo.2021.03.024","volume":"80","author":"Van der Heijden","year":"2021","journal-title":"Eur Urol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.1200\/JCO.2021.39.15_suppl.4532","volume":"39","author":"Bellmunt","year":"2021","journal-title":"J Clin Oncol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.eururo.2019.03.015","volume":"76","author":"Sternberg","year":"2019","journal-title":"Eur Urol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.euf.2020.09.010","volume":"7","author":"Tural","year":"2021","journal-title":"Eur Urol Focus"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1007\/s10147-021-01936-6","volume":"26","author":"Tural","year":"2021","journal-title":"Int J Clin Oncol"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s10147-021-02072-x","volume":"27","author":"Tural","year":"2022","journal-title":"Int J Clin Oncol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"5120","DOI":"10.1158\/1078-0432.CCR-19-4162","volume":"26","author":"Galsky","year":"2020","journal-title":"Clin Cancer Res"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"e172411","DOI":"10.1001\/jamaoncol.2017.2411","volume":"3","author":"Powles","year":"2017","journal-title":"JAMA Oncol"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S1470-2045(17)30900-2","volume":"19","author":"Patel","year":"2018","journal-title":"Lancet Oncol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur Urol"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1817323","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl J Med"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"17588359211047352","DOI":"10.1177\/17588359211047352","volume":"13","author":"Stecca","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/S1470-2045(21)00094-2","volume":"22","author":"Yu","year":"2021","journal-title":"Lancet Oncol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1200\/JCO.19.00538","volume":"37","author":"Sharma","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref46","unstructured":"MO Grimm, BJ Schmitz-Dr\u00e4ger, U Zimmermann, et al. Tailored immunotherapy approach with nivolumab in advanced transitional cell carcinoma (TITAN-TCC). Abstract from the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, Thursday Feb 17 \u2013 Saturday Feb 19; 2022."},{"key":"ref47","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.clgc.2021.04.001","volume":"19","author":"Marandino","year":"2021","journal-title":"Clin Genitourin Cancer"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"S678","DOI":"10.1016\/j.annonc.2021.08.047","volume":"32","author":"Sadeghi","year":"2021","journal-title":"Ann Oncol"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1158\/1078-0432.CCR-21-2210","volume":"28","author":"Sheng","year":"2022","journal-title":"Clin Cancer Res"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1080\/13543776.2021.1825688","volume":"31","author":"Cebada","year":"2021","journal-title":"Expert Opin Ther Pat"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1158\/2326-6066.CIR-15-0093-T","volume":"4","author":"Rhode","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1080\/14737140.2020.1807334","volume":"20","author":"Mollica","year":"2020","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1200\/JCO.2020.38.6_suppl.489","volume":"38","author":"Quinn","year":"2020","journal-title":"J Clin Oncol"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"v356","DOI":"10.1093\/annonc\/mdz249.016","volume":"30","author":"Siefker-Radtke","year":"2019","journal-title":"Ann Oncol"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1158\/1535-7163.MCT-21-0846","author":"Bouleftour","year":"2022","journal-title":"Mol Cancer Ther"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1200\/JCO.19.01140","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J Clin Oncol"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"28989","DOI":"10.18632\/oncotarget.25615","volume":"9","author":"Goldenberg","year":"2018","journal-title":"Oncotarget"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1200\/JCO.20.03489","volume":"39","author":"Tagawa","year":"2021","journal-title":"J Clin Oncol"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"C Vulsteke, P Grivas, ST Tagawa, et al. TROPiCS-04: study of Sacituzumab govitecan in patients with locally advanced unresectable or metastatic urothelial cancer that has progressed after prior platinum and checkpoint inhibitor therapy. Abstract from the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, Thursday Feb 17 \u2013 Saturday Feb 19; 2022.","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS582"}],"container-title":["Cancer Management and Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=81454","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=81454","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,13]],"date-time":"2022-06-13T10:10:15Z","timestamp":1655115015000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/treatment-options-for-metastatic-urothelial-carcinoma-after-first-line-peer-reviewed-fulltext-article-CMAR"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":60,"URL":"https:\/\/doi.org\/10.2147\/cmar.s287904","relation":{},"ISSN":["1179-1322"],"issn-type":[{"value":"1179-1322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6]]}}}